CollPlant Biotechnologies (CLGN) Income towards Parent Company (2017 - 2025)
CollPlant Biotechnologies (CLGN) reported Income towards Parent Company of -$3.2 million for Q4 2025, up 20.73% on a YoY basis from -$2.6 million in Q4 2024, and up 10.18% quarter-over-quarter from -$3.5 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Income towards Parent Company (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies has reported Income towards Parent Company for 9 years, with the latest figure at -$3.2 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company rose 20.73% year-over-year to -$3.2 million; the trailing twelve-month figure through Mar 2026 stood at -$3.5 million (down 41.31% YoY), and the FY2025 full-year result was -$11.1 million, up 32.76% from the prior year.
- Income towards Parent Company for Q4 2025 stood at -$3.2 million, up from -$3.5 million in the prior quarter.
- The five-year high for Income towards Parent Company was $193.9 million in Q3 2021, with the low at -$5.1 million in Q4 2023.
- Historically, Income towards Parent Company has averaged $9.3 million across 5 years, with a median of -$3.0 million in 2021.
- Annual changes were most pronounced in 2021 — Income towards Parent Company soared 698.75% — and 2022, when it slumped 102.3%.
- CollPlant Biotechnologies' Income towards Parent Company stood at -$3.8 million in 2021, then decreased by 22.92% to -$4.7 million in 2022, then fell by 8.38% to -$5.1 million in 2023, then climbed by 21.59% to -$4.0 million in 2024, then grew by 20.73% to -$3.2 million in 2025.
- The last three Income towards Parent Company figures came in at -$3.2 million (Q4 2025), -$3.5 million (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.15 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Sep 30, 2024 | -4.54 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | -5.07 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | 5.68 Mn |
| Mar 31, 2023 | 3.52 Mn |
| Dec 31, 2022 | -4.68 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -4.19 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | -3.80 Mn |
| Sep 30, 2021 | 193.91 Mn |
| Jun 30, 2021 | -2.93 Mn |
| Mar 31, 2021 | 10.10 Mn |